Treating ARID1A mutated cancers by harnessing synthetic lethality and DNA damage response

Jayaprakash Mandal³, Prativa Mandal¹, Tian-Li Wang³* and Ie-Ming Shih²*

Abstract
Chromatin remodeling is an essential cellular process for organizing chromatin structure into either open or close configuration at specific chromatin locations by orchestrating and modifying histone complexes. This task is responsible for fundamental cell physiology including transcription, DNA replication, methylation, and damage repair. Aberrations in this activity have emerged as epigenomic mechanisms in cancer development that increase tumor clonal fitness and adaptability amidst various selection pressures. Inactivating mutations in AT-rich interaction domain 1A (ARID1A), a gene encoding a large nuclear protein member belonging to the SWI/SNF chromatin remodeling complex, result in its loss of expression. ARID1A is the most commonly mutated chromatin remodeler gene, exhibiting the highest mutation frequency in endometrium-related uterine and ovarian carcinomas. As a tumor suppressor gene, ARID1A is essential for regulating cell cycle, facilitating DNA damage repair, and controlling expression of genes that are essential for maintaining cellular differentiation and homeostasis in non-transformed cells. Thus, ARID1A deficiency due to somatic mutations propels tumor progression and dissemination. The recent success of PARP inhibitors in treating homologous recombination DNA repair-deficient tumors has engendered keen interest in developing synthetic lethality-based therapeutic strategies for ARID1A-mutated neoplasms. In this review, we summarize recent advances in understanding the biology of ARID1A in cancer development, with special emphasis on its roles in DNA damage repair. We also discuss strategies to harness synthetic lethal mechanisms for future therapeutics against ARID1A-mutated cancers.

Keywords: ARID1A, Chromatin remodeling, Synthetic lethality, Cancer

Background
Targeting the DNA damage response (DDR) for cancer therapy has gained significant attention in recent years. This promise reflects the fact that many malignant neoplasms are defective in their DNA damage repair machineries, most commonly a result of molecular genetic alterations, either somatic or inherited, in genes critically involved in various repair pathways. The recent success of PARP inhibitors in treating homologous recombination-deficient ovarian high-grade serous carcinomas champions such endeavors and encourages basic scientists and oncologists to explore novel anti-cancer strategies on a basis of synthetic lethality [1, 2]. Those efforts aimed to further impair the specific DNA damage repair pathway and overload DNA damage beyond the repair capacity in cancer cells with a compromised repair system. In particular, alongside the traditional concept of targeting DDR enzymes such as PARP1, WEE1, and ATR, harnessing the epigenomic changes in cancer cells represents another exciting direction as DNA damage repair largely
depends on chromatin configuration [3]. The purpose of this review is to discuss how inactivating mutations in \textit{AT-rich interaction domain 1A (ARID1A)}, a component of the chromatin remodeling SWI/SNF complex, affect DNA damage repair in tumor cells. First, we briefly review the diverse key cellular functions of ARID1A. Next, we highlight the therapeutic potential by targeting the ARID1A synthetic lethal phenotype with inhibitors of PARP, ATR, or other agents in ARID1A-mutated tumors. We will also provide our insights into the promises and challenges in developing therapeutic strategies to treat cancers with ARID1A mutations.

\subsection*{ARID1A and chromatin remodeling mechanism}

The SWItch/Sucrose Non-fermentable (SWI/SNF) was originally identified in \textit{saccharomyces cerevisiae} in 1984 [4, 5]. The human form of SWI/SNF complex is known as BRG1/BRM associated factor complex (BAF complex) or mammalian SWI/SNF (mSWI/SNF) complex. The subunits of mSWI/SNF complex, which are encoded by 29 genes, are assembled into three distinct complexes: canonical BAF (cBAF), polybromo-associated BAF (PBAF), and non-canonical BAF (ncBAF) [6]. These subunits bind to the distal enhancer regions, promoter regions, and CCCTC-binding factor (CTCF)-binding sites at many genomic loci, facilitating DNA accessibility to various nuclear proteins and their complexes so they can perform their functions. A BAF complex uses an ATPase core to hydrolyze ATP, generating energy to relax heterochromatin (condensed form) into euchromatin (relaxed form) by nucleosome unwrapping, mobilization, and exchanging [7] (Fig. 1). BAFs also bind to several other nuclear proteins, and these mechanisms collectively enhance the accessibility of nuclear factors for transcriptional activation, DNA duplication, and DNA repair. Conversely, the polycomb repressor complex restores the heterochromatin state after BAF complex disengagement [8].

AT-rich interaction domain 1A (ARID1A) is one of the chromatin remodeling proteins belonging to the SWI/SNF complex. The cBAF complex contains several subunits within which ARID1A and ARID1B are mutually exclusive (Fig. 1). ARID1A is also known as Brahma-related associated factor 250a (BAF250a), SWI/SNF-related matrix-associated actin-dependent regulators of chromatin factor 1 (SMARCF1), B120, C1orf4, Osa1, or p270 [9, 10]. The gene encoding ARID1A is located on chromosome 1p36.11. ARID1A, a large (250 kDa) nucleocytoplasmic protein, is actively imported from cytoplasm to the nuclear compartment.
Nuclear ARID1A is degraded by the ubiquitin–proteasome system but its dynamic import–export across nuclear membrane favors its nuclear accumulation in normal cells as evidenced by its universal expression in nuclei from normal cells [11]. Thus, ARID1A has been reported to directly interact with DNA via its ARID domain using a consensus motif [12].

In humans, germline ARID1A mutation has been thought to be a genetic culprit in the Coffin-Siris syndrome, a neurodevelopmental disorder characterized by congenital malformation and developmental delay (OMIM: #614607) [13]. In rodent models, Arid1a transcripts and protein levels are highly increased during all stages of mouse embryonic development and its ablation leads to the loss of pluripotency, self-renewal of mouse embryonic stem (ES) cells, and severe developmental arrest [14, 15].

**ARID1A as a tumor suppressor**

The discovery of ARID1A as a tumor suppressor gene was made more than a decade ago by two sequencing-based studies. Both studies analyzed whole exomes and global mRNAs in rare subtypes of epithelial ovarian cancer, clear cell carcinoma, and endometrioid carcinoma and identified a high frequency of inactivating mutations occurring diffusely in ARID1A with resultant loss of protein expression, a characteristic of a tumor suppressor. The mutations lead to truncated proteins that are rapidly degraded, and thus, ARID1A is functionally inactivated. Subsequently, inactivating ARID1A mutations have been detected in a wide variety of human cancers, highlighting the epigenomic roles of ARID1A in cancer development [18, 19].

Loss of ARID1A expression can also be a result of ARID1A promoter hypermethylation [20], and it is likely that tumors use sequence mutations in both alleles, or promoter hypermethylation together with mutations in different alleles, to drive complete loss of ARID1A proteins, following the classical “two-hit” theory characterizing tumor suppressor genes. The resultant loss of ARID1A expression impairs the interaction of ARID1A with other SWI/SNF subunits in the nucleus [11]. Occasionally, in-frame insertions and deletions affecting the nuclear transporting signal are also detected in cancer tissues, and those mutants also result in loss of its nuclear expression [11].

Approximately ~6% of human cancers harbor inactivating mutations in ARID1A. Some of the cancer types showing the highest incidence of ARID1A inactivating mutations and loss of expression are clear cell ovarian cancer (~50%), endometrial cancers (~37%), gastric cancers (20–30%), bladder cancers (~20%), hepatocellular cancers (~14%), melanomas (~12%), colon cancers (~9%), and lung cancers (~8%) [21–23]. ARID1A mutations have also been studied for their potential role as biomarkers for predicting clinical outcomes in cancer patients [24].

In vitro cell models and genetically engineered mouse models have provided cogent evidence to support the functional role of ARID1A in tumor suppression [12, 25–29]. Those studies have also elucidated multiple mechanisms involved. Of most relevance, ARID1A regulates expression of proteins participating in cell cycle control and DNA repair after DNA damage and replication stress. Loss of ARID1A in colon and ovarian cancer cells results in epigenetic reprogramming at enhancer regions and reduction of the open chromatin mark, H3K27ac, subsequently leading to loss of transcription of nearest genes. ARID1A drives the BAF-complex to enhancer regions and helps maintain chromatin in the relaxed configuration [25, 30]. Other mechanisms that are affected due to ARID1A loss are defective control of cell cycle progression, DNA damage checkpoint, regulation of p53 downstream targets (CDKN1A and SMAD3), and regulation of telomerase activity [31, 32]. ARID1A is also involved in decatenation of newly replicated sister chromatids [33]. Defects in the decatenation checkpoint is responsible for aneuploidy and genomic instability [34]. In the following sections, we briefly describe the roles of ARID1A in transcriptional regulation and maintenance of DNA integrity in the context of DNA damage and replication stress.

**Transcriptional regulation by ARID1A**

ARID1A-mediated transcriptional regulation is mainly attributed to its chromatin accessibility role. ARID1A can increase or decrease chromosome accessibility histone marks at the promoter regions of genes and regulate their expression. ARID1A-mediated chromatin remodeling regulates transcription positively as well as negatively [35]. Generally, acetylation of histones (histone mark: H3K27ac) keeps the chromatin open, permitting DNA transcription to take place, whereas methylation of histones (histone mark: H3K9me3) keeps the chromatin closed, preventing transcription. For instance, ARID1A depletion decreases the open histone mark (H3K27ac) at the enhancer region and transcriptionally activates a number of cancer related genes including PIK3IP1 [36], SLC7A11 [37], CDKN1A, TGF-β receptor [12], and SMAD3 [38] among several others.

On the other hand, ARID1A depletion promotes expression of the deubiquitinating enzyme USP9X. Mechanistically, ARID1A recruits HDAC1 to the promoter of USP9X where it downregulates its expression by removing the acetyl group from histone. Conversely, depletion of ARID1A causes an increase
in the acetylation level H3K9 and H3K27 at the USP9X promoter, thereby increasing its expression [39]. Similarly, cells lacking ARID1A show increased transcription of HDAC6, AURKA, and TERT [31] associated with increased histone acetylation. ARID1A is seen to control global transcription by controlling RNA polymerase II (RNAPII) dynamics. ARID1A depletion represses RNAPII, which causes transcriptional dysregulation of several active genes. Although restoration of a mutually exclusive partner, ARID1B, rescues transcription of some of these genes, targets of p53 and estrogen receptor genes are not rescued [40].

Role of ARID1A in DNA damage response

In recent years, the emerging roles of ARID1A in the DNA damage response (DDR) have been established (Fig. 2). These new data not only furnish the means for understanding the fundamental biology of DDR but also suggest mechanisms for synthetic lethality when ARID1A is inactivated. DNA damage and replication stress initiate DDR through activities of two signaling proteins that detect these aberrant events: ATM (ataxia-telangiectasia mutated) and ATR (ATM and Rad3-Related). ATM is generally activated by a double-strand DNA break (DSB) whereas ATR is activated by a single-strand break (SSB), DNA replication stress [41], and DNA-end resection (which generates a single-strand DNA region during DSB repair). In S-phase, ATR is responsible for replication initiation, replisome stability, and replication fork restart, whereas in G2-phase it prevents premature mitotic advance. Inhibition of ATR interferes with the cell cycle and genomic stability, thus decreasing cell survival [42]. DNA DSBs are repaired by several major pathways in mammalian cells: non-homologous end joining (NHEJ), and homologous recombination (HR) repair pathways. In case of defective NHEJ or HR, alternative NHEJ provides a backup mechanism involving Poly (ADP-ribose) polymerase 1 (PARP1).

ARID1A-containing SWI/SNF complexes also allow DNA repair proteins to effectively access DNA damage sites [43]. Inactivation of SWI/SNF complex by deleting or knockdown of ARID1A compromises DNA DSB repair, increases sensitivity to DNA damaging agents, and impairs γ-H2AX induction [44]. Specifically, suppression

Fig. 2 Chromatin remodeling and role of ARID1A in maintaining genome integrity. Chromatin remodeling (nucleoside sliding and nucleosome eviction) by ARID1A-containing BAF complex is shown at left (see Fig. 1). Chromatin remodeling is required to open the chromatin structure to ensure easy accessibility of DNA repair proteins of various DNA repair pathways as shown on the right. ARID1A is directly involved in repairing DNA damage using DNA repair mechanisms such as BER, MMR, NHEJ, Alt-NHEJ, and HR and in resolving TRC and aberrant R-loops that give rise to replication stress. ARID1A AT-Rich Interaction Domain 1A, AP site apurinic/apyrimidinic site, BER base excision repair, PARP polyadenosine diphosphate-ribose polymerase, 53BP1 tumor suppressor p53-binding protein 1, RIF1 Replication Timing Regulatory Factor 1, NHEJ non-homologous end joining, HR homologous recombination, Alt-NHEJ alternate non-homologous end joining, DSB double-strands break, ATR ataxia telangiectasia and Rad3-related protein, TRC transcription-replication conflict, TOP2A DNA Topoisomerase II Alpha, MSH2 MutS homolog 2, MMR mismatch repair, MLH1 MutL homolog 1, ICB immune checkpoint blockade. Illustration created using Biorender.com
of ARID1A reduces NHEJ by decreasing the recruitment of NHEJ factors such as KU70/KU80 and the ATPase subunit of SWI/SNF complex to the DSB sites [45]. ARID1A knockout cells are unable to mount efficient NHEJ repair after irradiation, but largely spare PARP-mediated alt-NHEJ and DSB repair pathways. This is because 53BP1 and RIF1, key NHEJ factors, delay to arrive at the DSB sites due to ARID1A deficiency. As expected, a combination of low-dose irradiation and PARP inhibitor shows a synergistic cytotoxicity in ARID1A-deficient tumor cells in both in vitro and in vivo models [43].

ARID1A is also involved in repairing damaged DNA through homologous recombination (HR) repair. Mechanistically, ARID1A is recruited to DNA DSB sites through interacting with the upstream kinase, ATR. ARID1A also helps recruit the ATPase subunit of the SWI/SNF complex to DNA damage sites. Loss of ARID1A also impairs the G2/M DNA damage checkpoint. Overall, ARID1A facilitates DSB end resection and also helps maintain checkpoint signaling [46]. Thus, ARID1A protects the genome by interacting with the machinery of different DNA repair mechanisms.

**ARID1A, DNA mismatch repair, and immune checkpoint**

Alterations that lead to loss of expression of any genes such as *MSH2, MSH6, MLH1*, and *PMS2* or their combination in the mismatch repair (MMR) pathway contributes to DNA MMR deficiency, especially in endometrial and colorectal carcinomas. When the MMR pathway is defective, tumors show a high microsatellite instability (MSI-H) phenotype, producing up to thousands of somatic mutations in the genome, including many that encode neo-antigens which potentially trigger immune responses. *ARID1A* mutations have been found enriched in MSI-H neoplasms including endometrial carcinomas [47–49], ovarian carcinomas [50], gastric adenocarcinomas [51, 52], colon cancers [53, 54], and prostate cancers [55]. It remains uncertain if ARID1A is mechanistically involved in the mismatch repair process or if the *ARID1A* mutations are simply the result of the unstable hyper-mutated phenotype. There is some evidence supporting the former. In endometrial and colorectal cancer, ARID1A loss is associated with *MLH1* silencing resulting from promoter hypermethylation [49, 55].

As well, ARID1A has been shown to promote MMR by recruiting MSH2 to chromatin during DNA replication [56]. These findings imply that ARID1A plays a causal role in MMR.

Many ARID1A-mutated endometrial and colorectal carcinomas harbor the MSI-H phenotype. This finding is of significant clinical interest as the MSI-H phenotype provides a biomarker relevant to immunotherapy based on anti-PD1/PD-L1 drugs [54]. ARID1A transcriptionally regulates PD-L1 expression. *CD274*, which encodes PD-L1, is transcriptionally repressed by ARID1A [57]. As a result, loss of ARID1A predicts increased PD-L1 expression [58] via activating AKT signaling [59, 60].

These data suggest that ARID1A loss may help cancer cells, especially those with MMR deficiency, escape from immune checkpoint surveillance through upregulation of PD-L1.

**Role of ARID1A in replication stress response**

Replication stress characterizes cancer and is associated with incessant and uncontrolled cell replication [61]. Replication stress arises when replication forks are hindered by DNA abnormalities such as DNA lesions [62], R-loops, and secondary DNA structures. The replication stress response represents a deviation from a normal DNA replication program in rapidly dividing cancer cells with poor quality control during replication. In response to various DNA replication problems, activation of ATR kinase and its downstream effector kinase CHK1 is responsible for the replication stress response [63, 64]. ATR phosphorylates checkpoint kinases 1 and 2 (CHK1 and CHK2) to stall the replication cycle when single-stranded DNA breaks mount, giving cells time to repair their DNA. There are several sources of replication stress as discussed below.

**R-loops**

R-loops are three-stranded hybrid nucleic acid structures formed during a normal transcription process (Fig. 2). Physiologically, R-loops are involved in transcription initiation-termination, Ig class switch recombination, and telomerase elongation [65]. When the homeostasis of an R-loop is altered, the progression of replication is stalled by the phenomenon of transcription-replication conflict. During this conflict, machineries of DNA replication and transcription collide [66] leading to replication stress. If the stress is not effectively resolved in a timely manner, persistence of R-loops can become the source of replication stress and subsequent genomic instability [67, 68]. The presence of a persistent R-loop causes activation of the ATR pathway through an as yet unknown mechanism [69, 70]. Aberrant R-loops that fail to be resolved interfere with DNA damage repair and transcription [71] (reviewed in [68]). Recently, loss of ARID1A has been reported to lead to replication stress and R-loop formation [72]. ARID1A loss generates replication stress through DNA topoisomerase (TOP2A) mis-localization in the genome. By modulating DNA topology, TOP2A is involved in chromosome condensation, separation of chromatids, DNA replication, and transcription [73, 74].

Thus, ATR activation is critical for mitigating R-loop
aberrations, and the ATR pathway is responsible for protecting the genome by suppressing transcription-replication conflicts, promoting replication-fork recovery, and arresting cells at G2-M phase for further repair. These new data suggest that ATR inhibition may preferentially kill ARID1A-deficient tumors.

**DNA catenation**

Another source of replication stress is DNA catenation, an intermediate product of DNA replication. It is formed when two replication forks collide and DNA topoisomerase II removes these structures (known as decatenation) [75]. Mechanistically, TOP2A-mediated DNA decatenation requires BAF complex subunits such as BRG1 (SMARC4) and BAF250A (ARID1A) to bind to chromatin. In the absence of ARID1A, TOP2A is unable to complete this process before mitosis, and as a result, complex chromosomal structures can arise during DNA replication. Moreover, ARID1A loss leads to DNA decatenation defects in tumor cells, which is thought to be due to improper localization of TOP2A [33, 73]. TOP2A helps resolve topological issues brought on by chromosomal metabolism, such as catenated DNA and transcription-replication conflicts. It appears that the failure of TOP2A to properly localize in concert with delayed cell cycle progression in ARID1A deficient cells would result in an increased requirement for TOP2A, suggesting a therapeutic potential of ATR inhibitor.

**Apurinic/apyrimidinic site**

Apurinic/apyrimidinic site (AP sites), also known as abasic sites, are DNA repair intermediates that act as roadblocks to replication fork progression [61]. These lesions are generally repaired, but replicative DNA polymerases using the Translesion Synthesis (TLS) pathway can bypass these lesions if they are not resolved in a timely fashion [76]. Alkylating drugs like temozolomide and mitomycin-C methylate DNA bases and those methylated bases are repaired by both base excision repair (BER) and nucleotide excision repair (NER) [77]. Recently, we have observed that ARID1A-deficient cancer cells challenged with temozolomide and PARP inhibitor exhibited significant replication stress, replication fork instability, and DNA damage due to impaired BER arising from the ARID1A deficiency, leading to cell death (Fig. 2). We showed that ARID1A-deficient cancer cells developed a high susceptibility to PARP inhibitors in the presence of TMZ and link BER and TLS functionally. Loss of ARID1A delayed arrival of repair proteins at the AP sites compromising BER. Compromised BER and TLS may exacerbate replication fork stalling in ARID1A-deficient cells, resulting in fork collapse and cell death. Moreover, our preclinical study warrants further clinical testing for the FDA-approved alkylating agent TMZ and PARPi combination, which exhibits synergistic benefits in the ARID1A-deficient tumors (manuscript submitted).

**Therapeutic targeting of DDR pathway-synthetic lethality and combination**

Synthetic lethality is a phenomenon where the simultaneous loss of function of both genes causes cell death, whereas the inactivation of any one of two genes independently has no impact on cell survival. The idea of synthetic lethality in cancer has been expanded to include pairs of genes, where the inactivation of one gene through deletion or mutation and the pharmaceutical inhibition of the other results in the death of cancer cells, whereas normal cells are spared they do not have the fixed genetic alteration [78]. Since its discovery as a tumor suppressor, ARID1A has entered center stage as an agent for synthetic lethal drug screening. Synthetic lethal interactions provide a key avenue for development of cancer therapies. In anti-cancer therapy, by principle, inhibiting the functional products of such lethal gene partners should kill the cancer cells [79, 80] (Fig. 3). A landmark achievement based on synthetic lethality in cancer was the discovery of poly (ADP-ribose) polymerase (PARP) inhibitor in BRCA1/2 mutated ovarian cancer [1, 2]. In the following, we will discuss the promise in ARID1A synthetic lethal phenotypes using PARP inhibitor, ATR inhibitor, and other emerging agents.

**Targeting ATR and PARP**

It has become clear that loss of ARID1A impedes genome stability after DNA damage. Since genomic stability is essential for normal cells to survive, several repair pathways have evolved to protect the genome. It is not surprising that upon ARID1A loss, other pathways will compensate for its loss of function. Thus, targeting those complementary pathways holds promise in developing new cancer therapies in ARID1A deficient neoplasms. The role of ATR, PARP1, and TOP2A in maintaining genome integrity is pivotal as discussed in the previous section. To reiterate, after ARID1A loss, ATR signaling is activated as a result of replication stress due to transcription-replication conflicts, aberrant R-loop formation, defective decatenation process, and DNA damage. Thus, inhibition of ATR can theoretically eliminate ARID1A-deficient cancer cells. In fact, ATR inhibitors have been reported to act in a synthetic lethal way in ARID1A-deficient cancer [73]. ATR inhibition has been shown to disrupt BRCA1-independent loading of RAD51 at DSBs causing stalled forks and to be effective in overcoming resistance to PARP inhibitor in cancer cells exhibiting BRCAness [81]. As several ATR inhibitors have entered into clinical studies, targeting ATR holds promise to
treat ARID1A mutated cancers. In fact, a combination of ATR inhibitor (ceralasertib) and PARP inhibitor (olaparib) has been proposed as a model to overcome PARP inhibitor resistance (NCT02576444, Table 1) in patients with relapsed or refractory malignancies exhibiting DDR changes. ATR inhibitor may elicit ATM activation to compensate for its inactivation (Fig. 4). This feature provides a rationale for targeting both stress kinases (ATM/ATR) in ARID1A-deficient cancers. Recently, it was reported that ARID1A-deficient tumors exhibited high expression of Chk2. Loss of ARID1A altered E3-ligase RNF8-mediated degradation of Chk2. Since Chk2 is a downstream kinase of ATM, inhibition of the ATM/Chk2 axis in ARID1A deficient cells led to replication stress, increased tumor-infiltrating lymphocytes, and a STING-mediated innate immune response resulting in longer patient survival [82].

In addition to ATR inhibition [73], TOP2A and PARP1 can also be targeted in ARID1A-deficient tumors as a combination therapy. These two molecules (ARID1A and ATR) are synthetic lethal partners [83] and increase the sensitivity to PARP inhibitors [46]. However, a known clinical challenge seen in PARP inhibitor is its acquired resistance that is best characterized by a BRCA reversion mutation that partially or fully restores its tumor suppressor function. Another challenge is the hematological toxicity associated with certain clinically used PARP inhibitors. Alongside PARP enzymatic inactivation, first-generation PARP inhibitors trap PARP1 and PARP2 at the DNA damage sites. Both repair proteins are required to activate the DDR pathway, and because of the trapping, cells cannot efficiently repair damaged DNA, leading to cytotoxicity not only for cancer cells but also for normal cells. The subsequent development of a selective PARP1 inhibitor showed a low level of toxicity and a high therapeutic index (AZD5305 phase I/II PETRA trial).

Emerging non-DDR synthetic lethal partners
In addition to PARP and ATR, there are several existing (reviewed in: [83–88]) and emerging non-DDR synthetic lethal partners, targeting of which may lead to increased cytotoxicity in ARID1A-deficient tumors (Fig. 5).

Polo-like kinase 1 (PLK1) belongs to the serine-threonine kinase family. PLK1 plays a critical role in advancement of the cell cycle to mitosis by promoting mitotic spindle assembly, cell division, DNA-damage response,
| Target group                                    | Clinical trial ID         | Study title                                                                 | Drug (target)          | Disease                                      | Study phase | Status              |
|------------------------------------------------|---------------------------|------------------------------------------------------------------------------|------------------------|----------------------------------------------|-------------|---------------------|
| Targeting DDR, ICB and combination             | NCT02278250              | First in human study of M4344 in participants with advanced solid tumors    | M4344 (ATRi)           | Advanced solid tumors                        | 1           | Completed           |
|                                               | NCT03718091              | M6620 (VX-970) in selected solid tumors                                      | M6620 (ATRi)           | Solid tumor                                  | 2           | Completed           |
|                                               |                           | Olaparib in treating patients with metastatic biliary tract cancer with aberrant DNA repair gene mutations | Olaparib (PARPi)       | Biliary tract cancer                         | 2           | Recruiting          |
|                                               |                           | A trial of niraparib in BAP1 and other DNA damage response (DDR) deficient neoplasms (UP-STO-ETH-001) | Niraparib (PARPi)      | Mesothelioma                                  | 2           | Active, not recruiting |
|                                               |                           | Niraparib monotherapy as maintain and recurrent treatment of endometrial serous carcinoma | Niraparib (PARPi)      | Endometrial carcinoma                         | 2           | Recruiting          |
|                                               | NCT04065269/ATARI         | Atr inhibitor in combination with olaparib in gynecological cancers with arid1a loss or no loss | AZD6738 (ATRi) Olaparib (PARPi) | Gynecological cancers                        | 2           | Recruiting          |
|                                               |                           | Phase II trial of AZD6738 alone and in combination with olaparib             | AZD6738 (ATRi) Olaparib (PARPi) | Advanced cancers                             | 2           | Recruiting          |
|                                               | NCT04953104              | Olaparib combinations                                                       | AZD6738 (ATRi) AZD2281 (PARPi) AZD5363 (AKT1) AZD1775 (WEE1i) | Cancer                                              | 2           | Not yet recruiting   |
|                                               |                           | Phase II study of olaparib and pembrolizumab in advanced melanoma with homologous recombination (HR) mutation | Olaparib (PARPi) Pembrolizumab (PD-1i) | Metastatic melanoma                           | 2           | Recruiting          |
|                                               | NCT04957615              | Nivolumab for the treatment of metastatic or unresectable solid tumors with ARID1A mutation and CXCL13 expression | Nivolumab (PD-1i) | Metastatic malignant solid neoplasm          | 2           | Not yet recruiting   |
| Target group | Clinical trial ID | Study title | Drug (target) | Disease | Study phase | Status |
|--------------|------------------|-------------|---------------|---------|-------------|--------|
| Targeting epige-netics, ICB and combination | NCT05154994/RESOLVE | Tremelimumab, durvalumab, and belinostat for the treatment of ARID1A mutated metastatic or unresectable, locally advanced urothelial carcinoma | Belinostat (HDACi) Durvalumab (PD-L1i) Tremelimumab (CTLA-4i) | Urothelial carcinoma | 1 | Recruiting |
| NCT04493619 | PLX2853 as a single agent in advanced gynecological malignancies and in combination with carboplatin in platinum-resistant epithelial ovarian cancer | PLX2853 (BETi) Carboplatin | | Gynecologic neoplasms | 1, 2 | Active, not recruiting |
| NCT03297424 | A Study of PLX2853 in Advanced Malignancies | PLX2853 (BETi) | | Advanced malignancies | 1, 2 | Completed |
| NCT05023655 | Phase II study of tazemetostat in solid tumors harboring an ARID1A mutation | Tazemetostat (EZH2i) | | Solid tumors | 2 | Recruiting |
| NCT03348631 | Tazemetostat in treating patients with recurrent ovarian or endometrial cancer | Tazemetostat (EZH2i) | | Recurrent ovarian or endometrial cancer | 2 | Suspended |
| NCT04104776 | A study of CPI-0209 in patients with advanced solid tumors and lymphomas | CPI-0209 (EZH2i) | | Advanced solid tumor and lymphomas | 1, 2 | Recruiting |
| Targeting kinases | NCT02059265 | Dasatinib in treating patients with recurrent or persistent ovarian, fallopian tube, endometrial or peritoneal cancer | Dasatinib (Multikinase inhibitor) | Recurrent gynecologic cancer | 2 | Active, not recruiting |
| NCT01914510 | A study of ENMD-2076 in ovarian clear cell cancers | ENMD-2076 (Multikinase inhibitor) | | Ovarian clear cell carcinoma | 2 | Completed |

1 inhibitor, ATR ataxia telangiectasia and Rad3-related inhibitor, PARP poly adenosine diphosphate-ribose polymerase, PD-1 programmed cell death protein 1, PD-L1 programmed death ligand-1, CTLA-4 cytotoxic T-lymphocyte-associated protein 4, HDAC histone deacetylase, BET bromodomain and extra-terminal motif, EZH2 enhancer of zeste homolog 2.
and maintenance of genomic stability. Overexpression of PLK1 has been reported to enhance proliferation rate and enhance tumorigenicity. Conversely, its inhibition causes reduction of proliferation and apoptosis in cancer cells but not in normal cells, suggestive of a potential role as a cancer therapeutic agent [89]. However, clinical progress using PLK1 inhibitor has been limited likely due to a lack of biomarkers capable of identifying patients whose tumors are vulnerable to this inhibitor. Recently, the role of PLK1 in ARID1A-deficient cancer cells has been reported. Cells lacking ARID1A are highly sensitive to PLK1 inhibition [90]. Interestingly, the sensitivity is related to mitochondrial metabolism rather than to the known role of PLK1 in cell division. ARID1A knockout cells exhibit altered mitochondrial biogenesis showing a higher number of globular mitochondria, increased oxidative phosphorylation, and increased oxygen consumption without increased ATP production. Interestingly, PLK1 is localized at mitochondria, and this may explain why PLK1 inhibition is associated with exaggerated mitochondrial oxygen consumption and membrane depolarization, leading to apoptosis. To further explore the therapeutic potential of targeting PLK1 in the context of ARID1A deficiency, PLK1 inhibition may be combined with chemotherapeutic agents and PARP inhibitor. To this end, PLK1 is reported to increase the temozolomide sensitivity in glioma stem cells [91]. Recently, the combination of temozolomide and PLK1 inhibitor has shown synergistic cytotoxicity in glioma cells in vivo [92].

USP9X (ubiquitin-specific peptidase 9 X-linked) is a deubiquitinase which regulates the protein levels of its substrates through proteasomal degradation. USP9X is involved in cancer initiation and development [93, 94], and intriguingly, its role in cancer has both pro-oncogenic [95] and tumor suppressor functions, likely depending on tissue context [96, 97]. High expression of USP9X confers resistance to gemcitabine and cisplatin in pancreatic cancer [98] and breast cancer [99], respectively. USP9X

---

**Fig. 4** Overview of targeting DNA damage response pathway in the context of ARID1A-deficiency (see text for description). Illustration created using Biorender.com
is also involved in DNA damage repair and DNA replication processes [100]. Loss of USP9X has been shown to cause accumulation of the double-strand break marker, γ-H2AX. This is likely because USP9X regulates the mRNA expression levels of BRCA1 and RAD51. Therefore, loss of USP9X decreases the BRCA1 and RAD51 mRNA levels, compromising their HR repair capacity. As expected, depletion of USP9X causes inefficient DSB repair and is synthetic lethal to PARP (poly (ADP-ribose) polymerase) inhibition [101].

Recently, the role of USP9X in ARID1A-deficient hepatocellular carcinoma was reported to involve a synthetic lethal interaction between ARID1A deficiency and inactivation of adenosine 5′-monophosphate-activated protein kinase (AMPK) [39]. Thus, a novel ARID1A-HDAC1-USP9X-AMPK axis in cancer is proposed. In non-transformed cells, ARID1A recruits HDAC1 which deacetylates H3K9 and H3K27 to epigenetically silence USP9X, and further downregulates its downstream substrate, AMPK. In a glucose-deprived condition, ARID1A-proficient cells undergo cell death following proteasomal degradation of protein kinase AMP-activated catalytic subunit α2 (PRKAA2) due to its role in silencing USP9X. However, in ARID1A-deficient cells, USP9X is upregulated and blocks proteasomal degradation by deubiquitinating PRKAA2 (K364 residue) conferring cell survival. Thus, targeting this AMPK pathway leads to cell death preferentially in ARID1A-deficient cancer cells. Further studies are warranted to validate this synthetic lethal effect in different types of human cancer.

**Prognostic potential of ARID1A**

Synthetic lethality-based targeting vulnerabilities of ARID1A deficiency exploits the high mutational burden in many malignancies. Thus, ARID1A deficiency has the potential as a biomarker for precision medicine in various cancers. Loss of ARID1A, a tumor suppressor gene, has been shown to have significant prognostic value in several malignancies, gastric cancer [103–105], lung cancer [106], hepatocellular carcinoma [107–109], breast cancer [110], osteosarcoma [111], clear cell renal carcinoma [112, 113], and small intestinal carcinoma [114]. ARID1A loss has shown adverse (tumor progression, poor prognosis, lower survival, chemotherapy resistance,
early recurrence), beneficial (enhance patient survival) or no effect on progression-free survival and overall survival of cancer patients (for review [115]). In gynecologic cancers, loss of ARID1A is also regarded as an independent prognostic biomarker. For instance, reduced ARID1A expression has been correlated with the FIGO (International Federation of Gynecology and Obstetrics) stage, shorter progression-free survival in ovarian clear cell carcinoma [116, 117], endometrium-related cancers, and cervical cancer [118]. Conversely, several studies reported having no difference between ARID1A-negative and ARID1A-positive staining groups in terms of clinical stage, grade, histopathologic features, and overall survival in various gynecologic malignancies [119–123]. There could be several factors involved for such ambiguous prognostic role of ARID1A within the same cancer type. Those factors include limited sample size, lack of common choice of anti-ARID1A antibodies (for IHC) or concomitant mutations like PIK3CA, TP53, EZH2, KRAS as in ARID1A-deficient gynecological cancers that impact the prognosis in these cancers. Moreover, it is rare for a single gene to serve as a significant prognostic marker. Instead, a group of markers may serve better for this purpose. For instance, ARID1A, p53, and β-Catenin in combination may have a better prognostic potential in ovarian clear cell and endometrioid subtypes [124].

Concluding remarks and perspectives
ARID1A has emerged as one of the major tumor suppressor genes in many types of human cancer, especially those arising from the endometrial epithelium. Somatic mutations of ARID1A have been shown to alter the chromatin landscape and to affect several fundamental cellular functions including transcription, DNA hypermethylation, DNA synthesis, and DNA damage response. In recent years, ARID1A mutation has been explored for synthetic lethal targeting, and certain epigenetic drugs and inhibitors in the DNA damage repair have shown promise for treating ARID1A-mutated tumors. Immune checkpoint blocking is also currently being evaluated for efficacy in controlling ARID1A-mutated cancers. Despite the promise, several challenges need to be overcome before ARID1A-based precision oncology becomes a reality.

Foremost, the functional difference between the SWI/SNF complex in the presence and absence of ARID1A remains to be fully determined. Because of the mutually exclusive nature of subunits ARID1A and ARID1B, when ARID1A is missing, ARID1B can substitute for ARID1A in SWI/SNF complexes in maintaining DNA accessibility to various nuclear proteins. The knowledge whether ARID1A-containing complex and ARID1B-containing complex show different specificity to bind to DNA loci or the subunit alter the chromatin remodeling activity is important to understand the pathogenesis in tumor cells losing ARID1A, and help discover the synthetic lethal strategies.

Second, identification and validation of biomarkers to predict treatment outcomes using synthetic lethal drugs like EZH2 inhibitor and PARP inhibitor is important for development of effective targeted therapies. Intuitively, ARID1A mutation or loss of expression can be an ideal tissue biomarker, but clinical validation is required to affirm this conclusion. It is uncertain if monoallelic inactivation (mutation, ch1p36 deletion, or epigenetic silencing) share some phenotypes as bi-allelic inactivation. Other biomarkers involved in various DNA damage repair pathways can also be explored for outcome correlations in ongoing and future clinical trials.

Third, despite the well-described clinical benefits of targeted cancer therapy, drug resistance to monotherapy is inevitable due to the expansion of tumor clones that are refractory to the targeted therapeutic agent under an ever-changing tumor microenvironment. Combinational therapy provides a possible solution for this significant clinical problem but increased adverse effects can become more apparent. A better dosing and scheduling strategy in a well-defined clinical setting is warranted to deliver effective therapy to ARID1A-mutated malignancies.

Abbreviations
ARID1A: AT-Rich Interaction Domain 1A; AP site: Apurinic/apyrimidinic site; BER: Base excision repair; PARP: Poly adenosine diphosphate-ribose polymerase; 53BP1: Tumor suppressor p53-binding protein 1; RIF1: Replication Timing Regulatory Factor 1; NHEJ: Non-homologous end joining; HR: Homologous recombination; Alt-NHEJ: Alternate non-homologous end joining; DSB: Double-strand break; ATR: Ataxia telangiectasia and Rad3-related protein; TRC: Transcription-replication conflict; TOP2A: DNA Topoisomerase II Alpha; MSH2: MutS homolog 2; MMR: Mismatch repair; MLH1: MutL homolog 1; ICB: Immune checkpoint blockade; PD-1: Programmed cell death protein 1; PD-L1: Programmed death ligand-1; CTLA-4: Cytotoxic T-lymphocyte-associated protein 4; HDAC: Histone deacetylase; BET: Bromodomain and Extra-Terminal motif; EZH2: Enhancer of zeste homolog 2.

Acknowledgements
Not applicable.

Author contributions
JM and IMS contributed to the conception and writing of the manuscript. JM prepared the original draft. PM and TLW contributed substantially to writing and review of the manuscript. IMS supervised the review. All authors read and approved the final manuscript.

Funding
This review article is supported by the following resources: Richard W. TeLinde Endowment, Johns Hopkins University, Breakthrough Cancer Foundation, NIH/NCI P01CA22899 and CA215483.

Availability of data and materials
Not applicable.
Declarations

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare no competing interests.

Author details
1 BP Koirala Institute of Health Sciences, Dharan, Nepal. 2 Department of Gynecology and Obstetrics, Johns Hopkins University School of Medicine, Baltimore, USA. 3 Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Received: 2 August 2022 Accepted: 13 September 2022 Published online: 19 September 2022

References

1. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434(7035):913–7.
2. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434(7035):917–21.
3. Stadler J, Richly H. Regulation of DNA repair mechanisms: how the chromatin environment regulates the DNA damage response. Int J Mol Sci. 2017;18(8):1715.
4. Neugeboren L, Carlson M. Genes affecting the regulation of SUC2 gene expression by glucose repression in Saccharomyces cerevisiae. Genetics. 1984;108(4):845–58.
5. Wang W, Côté J, Xue Y, Zhou S, Khavarai PA, Biggar SR, et al. Purification and biochemical heterogeneity of the mammalian SWI-SNF complex. EMBO J. 1996;15(19):5370–82.
6. Matsuñori N, D’Avino AR, Michel BC, Luo J, Pan J, Otto JE, et al. Modular organization and assembly of SWI/SNF family chromatin remodeling complexes. Cell. 2018;175(5):1272–1288.e20.
7. Sokpor G, Xie Y, Rosenbusch J, Tuoc T. Chromatin remodeling BAF (SWI/SNF) complexes in neural development and disorders. Front Mol Neurosci. 2017;10:243.
8. Kadoch C, Williams RT, Calarco JP, Miller EL, Weber CM, Braun SM, et al. Dynamics of BAF-polycomb complex opposition on heterochromatin in normal and oncogenic states. Nat Genet. 2017;49(2):213–22.
9. Wu RC, Wang TL, Shih IM. The emerging roles of ARID1A in tumor suppression. Cancer Biol Ther. 2014;15(6):655–64.
10. Xu S, Tang C. The role of ARID1A in tumors: tumor initiation or tumor suppression? Front Oncol. 2021;11:745187.
11. Guan B, Gao M, Wu CH, Wang TL, Shih IM. Functional analysis of in-frame indel ARID1A mutations reveals new regulatory mechanisms of its tumor suppressor functions. Neoplasia. 2012;14(10):986–93.
12. SuryoRahmanto Y, Jung JG, Wu RC, Kobayashi Y, Heaphy CM, Meeker AK, et al. Inactivating ARID1A tumor suppressor enhances TERT transcription and maintains telomere length in cancer cells. J Biol Chem. 2016;291(18):9690–9.
13. Guan B, Mao TL, Panuganti PK, Kuhn E, Kurman RJ, Maeda D, et al. Mutation and loss of expression of ARID1A in uterine low-grade endometrioid carcinoma. Am J Surg Pathol. 2013;35(5):625–32.
14. Dykhuizen EC, Hargreaves DC, Miller EL, Cui K, Korshunov A, Kool M, et al. BAF complexes facilitate decatenation of DNA by topoisomerase IIα. Nature. 2013;497(7451):624–7.
15. Damelin M, Bestor TH. The decatenation checkpoint. Br J Cancer. 2007;96(2):201–5.
16. Kelso TWR, Porter DK, Amoral ML, Shokhirev MN, Benner C, Hargreaves DC. Chromatin accessibility underlies synthetic lethality of SWI/SNF subunits in ARID1A-mutant cancers. Elife. 2017;6:e30506.
17. Bitler BG, Aird KM, Ganpav A, Li H, Amatangelo M, Kossenkov AV, et al. Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers. Nat Med. 2015;21(3):231–8.
18. Ogiwara H, Takahashi K, Sasaki M, Kuroda T, Yoshida H, Watanabe R, et al. Targeting the vulnerability of glutathione metabolism in ARID1A-deficient cancers. Cancer Cell. 2019;35(2):177–190.e6.
19. Guan B, Wang TL, Shih IM. ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers. Can Res. 2011;71(21):6718–27.
39. Zhang FK, Ni QZ, Wang K, Cao HJ, Guan DX, Zhang EB, et al. Targeting USP9X-AMPK axis in ARID1A-deficient hepatocellular carcinoma. Cell Mol Gastroenterol Hepatol. 2022;4(1):101–72.

40. Trizano M, Barbieri E, Petracovici A, Wu S, Welsh SA, Owens TA, et al. The tumor suppressor ARID1A controls global transcription via pausing of RNA polymerase II. Cell Rep. 2018;23(13):3933–45.

41. Marechal A, Zou L. DNA damage sensing by the ATM and ATR kinases. Cold Spring Harb Perspect Biol. 2013;5(9): a012716.

42. Maréchal A, Zou L. DNA damage sensing by the ATM and ATR kinases. Cell Rep. 2018;23(13):3933–45.

44. Park JH, Park EJ, Lee HS, Kim SJ, Hur SK, Imbalzano AN, et al. Mamma‑miR‑375b inhibits PD‑L1 synthesis and promotes immune evasion. J Mol Biol. 2022;434(1):601–14.

46. Khalique S, Nash S, Natrajan R. Definitive study shows no association between ARID1A mutation status and clinical outcome in endometriosis related ovarian cancers. J Pathol. 2022;258(1):1–3.

49. Bosse T, ter Haar NT, Seeber LM, Diest PJ, Hes FJ, Vasen HF, et al. Loss of ARID1A expression is tightly associated with high PD‑L1 expression in gastric cancer. Int J Cancer. 2020;147(1):210–16.

50. Wang K, Kan J, Yuen ST, Shi ST, Chu KM, Law S, et al. Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer. Cancer Discov. 2015;5(7):752–67.

53. Jones S, Li M, Parsons DW, Zhang X, Wesseling J, Kristel P, et al. Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types. Hum Mutat. 2012;33(1):100–3.

54. Cerecak A, Lumish M, Sinopoli J, Weiss J, Shia J, Lamendon-Essel E, et al. PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer. N Engl J Med. 2022;386(5):2563–76.

55. Ye J, Zhou Y, Weiser MR, Gönen M, Zhang L, Samdani T, et al. Immunohistochemical detection of ARID1A in colorectal cancer: loss of staining is associated with sporadic microsatellite unstable tumors with medullary histology and high TNM stage. Hum Pathol. 2014;45(12):2430–6.

56. Shen J, Ju J, Zhao W, Wang L, Peng Y, Ge Z, et al. ARID1A deficiency promotes mutability and potentiates therapeutics and immunity. Cancer Discov. 2017;7(1):90–103.

57. Fukumoto T, Paskhutdinov N, Zundell JA, Tcgyanov EN, Nacarelli T, Karakashov E, et al. HDAC6 inhibition synergizes with anti-PD-L1 therapy in ARID1A-inactivated ovarian cancer. Cancer Res. 2021;81(15):5482–9.

58. Nan L, Wang C, Wang J, Zhang S, Bo X, Wang Y, et al. ARID1A downregulation predicts high PD-L1 expression and worse clinical outcome in patients with bladder cancer. Front Oncol. 2022;12:788797.

59. Kim YB, Ahn JM, Bae WJ, Sung CO, Lee D. Functional loss of ARID1A is tightly associated with high PD-L1 expression in gastric cancer. Int J Cancer. 2019;145(4):916–26.

60. Ideh N, Itoh S, Yoshizumi T, Yugawa K, Morinaga A, Tomiyama T, et al. ARID1A deficiency is associated with high programmed death ligand 1 expression in hepatocellular carcinoma. Hepatol Commun. 2021;5(4):675–88.

61. Savina S, Zou L. Hallmarks of DNA replication stress. Mol Cell. 2022;82(12):2298–314.

62. Ashour ME, Mosammamparast N. Mechanisms of damage tolerance and repair during DNA replication. Nucleic Acids Res. 2021;49(6):3033–47.

63. Forment JV, O'Connor MJ. Targeting the replication stress response in cancer. Pharmacol Ther. 2018;188:155–67.

64. Desany BA, Alcasabas AA, Bachant JB, Elledge SJ. Recovery from DNA replication stress is the essential function of the S-phase checkpoint pathway. Genes Dev. 1998;12(18):2956–70.

65. Sollier J, Cimprich KA. Breaking bad: R-loops and genome integrity. Trends Cell Biol. 2015;25(9):514–22.

66. Hamperl S, Cimprich KA. Conflict resolution in the genome: how transcription and replication make it work. Cell. 2016;167(6):1455–67.

67. Santose-Pereira JM, AguilerA A. R loops: new modulators of genome dynamics and function. Nat Rev Genet. 2015;16(10):583–97.

68. Rinaldi C, Pizzul P, Longhese MP, Bonetti D. Sensing R-Loop-associated DNA damage to safeguard genome stability. Front Cell Dev Biol. 2020;8:618157.

69. Hamperl S, Bocek MJ, Saldivar JC, Svigut T, Cimprich KA. Transcription-replication conflict orientation modulates r-loop levels and activates distinct DNA damage responses. Cell. 2017;170(4):774-786.e19.

70. MatoS DA, Zhang JM, Ouyang J, Nguyen GD, Genois MM, Zou L. ATR protects the genome against RLoops through a MUS81-triggered feedback loop. Mol Cell. 2020;77(3):514-527.e4.

71. Bayon–Felix E, Bantos S, Muñoz S, AguilerA A. The SWI/SNF chromatin remodeling complex helps resolve r-loop-mediated transcription–replication conflicts. Nat Genet. 2021;53(7):1050–63.

72. Tsai S, Fournier LA, Chang EY, Wells JP, Minaker SW, Zhu YD, et al. ARID1A regulates R-loop-associated DNA replication stress. PLoS Genet. 2017;13(4):e1007238.

73. Williamson CT, Miller P, Pemberton HN, Jones SE, Campbell J, Konde A, et al. ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A. Nat Commun. 2016;7:13837.

74. Nielsen CF, Zhang T, Barisic M, Kalttis P, Hudson DF. Topoisomerase IIa is essential for maintenance of mitotic chromosome structure. Proc Natl Acad Sci USA. 2020;117(22):12131–42.

75. Díaz-Martínez LA, Giménez-Abián JF, Clarke DJ. Chromosome cohesion—hinges, knots, ori and checkpoint. J Cell Sci. 2008;121(Pt 13):2107–14.
85. Takahashi K, Takenaka M, Okamoto A, Bowtell DDL, Kohno T. Treatment strategies for ARID1A-deficient ovarian clear cell carcinoma. Cancers (Basel). 2021;13(8):1769.
86. Cheng X, Zhao JX, Dong F, Cao XC. ARID1A mutation in metastatic breast cancer: a potential therapeutic target. Front Oncol. 2021;11:759577.
87. Hu G, Tu W, Yang L, Peng G, Yang L. ARID1A deficiency and immune checkpoint blockade therapy: from mechanisms to clinical application. Cancer Lett. 2020;473:148–55.
88. Mathur R. ARID1A loss in cancer: towards a mechanistic understanding. Pharmacol Ther. 2018;190:15–23.
89. Shakeel I, Basheer N, Hasan GM, Afzal M, Hassan MI. Polo-like kinase 1 as an emerging drug target: structure, function and therapeutic implications. J Drug Target. 2021;29(2):168–84.
90. Srinivas US, Tay NC, Jaynes P, Anbuselvan A, Ramachandran GK, War‑chandran T, et al. PLK1 inhibitor selectively induces apoptosis in ARID1A deficient cells through uncoupling of oxygen consumption from ATP production. Oncogene. 2022;41(13):1986–2002.
91. Liu N, Hu G, Wang H, Li Z, Guo Z. PLK1 inhibitor facilitates the suppressing effect of temozolomide on human brain glioma stem cells. J Cell Mol Med. 2018;22(11):5300–10.
92. Shi H, Sun S, Xu H, Zhao Z, Han Z, Jia J, et al. Combined delivery of temozolomide and siPLK1 using targeted nanoparticles to enhance temozolomide sensitivity in glioma. Int J Nanomed. 2020;15:3347–62.
93. Wei B, Xu L, Hu H, Sun Y, Wu J. USP9X mRNA expression predicts clinical outcome for esophageal squamous cell carcinoma treated with cisplatin-based therapy. Clin Res Hepatol Gastroenterol. 2020;44(6):932–8.
94. Murtaza M, Jolly LA, Gecz J, Wood SA. LA FAM fatale: USP9X in development and disease. Cell Mol Life Sci. 2021;78(21):4207–19.
95. Peng J, Hu Q, Liu W, He X, Cui L, Chen X, et al. USP9X expression correlates with tumor progression and poor prognosis in esophageal squamous cell carcinoma. Diagn Pathol. 2013;8:177.
96. Zhu C, Ji X, Zhang H, Zhou Q, Cao X, Tang M, et al. Deubiquitylase USP9X suppresses tumorigenesis by stabilizing large tumor suppressor kinase 2 (LATS2) in the Hippo pathway. J Biol Chem. 2018;293(4):1178–91.
97. Khan OM, Carvalho J, Spencer-Dene B, Mitter R, Frith D, Snijders AP, et al. The deubiquitinating enzyme USP9X regulates FBW7 stability and suppresses colorectal cancer. J Clin Investig. 2018;128(4):1326–37.
98. Ma T, Chen W, Zhi X, Liu H, Zhou Y, Chen BW, et al. USP9X inhibition improves gemcitabine sensitivity in pancreatic cancer by inhibiting autophagy. Cancer Lett. 2018;436:129–39.
99. Li L, Liu T, Li Y, Wu C, Luo K, Yin Y, et al. The deubiquitinating enzyme USP9X promotes tumor cell survival and confers chemoresistance through YAP1 stabilization. Oncogene. 2018;37(18):4242–31.
100. McCarragh EB, Gaboriau DR, Rainey MD, Restuccia U, Bachi A, Santocanale C. The deubiquitinase USP9X maintains DNA replication fork stability and DNA damage checkpoint responses by regulating CLASPIN during S-Phase. Cancer Res. 2016;76(8):2384–93.
101. O’Dea R, Santocanale C. Non-canonical regulation of homologous recombination DNA repair by the USP9X deubiquitylase. J Cell Sci. 2020;133(3):jcs233437.
102. Elbaek CR, Petrosius V, Skovsgaard TS, Csanaki G. OARCA-1 positive expression in gastric cancer. Sci Rep. 2019;9(1):6769.
103. Zhu YP, Sheng LL, Wu J, Yang M, Cheng XF, Wu NN, et al. Loss of ARID1A expression is associated with poor prognosis in patients with gastric cancer. JAMA Oncol. 2020;6(10):1509–15.
104. Lowery WJ, Schildkraut JM, Akushevich L, Bentley R, Marks JR, Huntsman D, et al. Loss of ARID1A-associated protein expression is a frequent event in endometriosis-associated ovarian cancers. J Pathol. 2022;256(4):388–401.
105. Ashizawa M, Saito M, Min AKT, Ujiie D, Saito K, Sato T, et al. Prognostic value of ARID1A expression in breast cancer: a potential therapeutic target. J Exp Clin Cancer Res. 2015;34(1):47.
106. Cho HD, Lee JE, Jung HY, Oh MH, Lee JH, Jang SH, et al. Loss of ARID1A is a potential diagnostic marker in metastatic prostate cancer. J Exp Clin Cancer Res. 2015;34(1):47.
107. Cho HD, Lee JE, Jung HY, Oh MH, Lee JH, Jang SH, et al. Loss of ARID1A in prostate cancer is associated with poor prognosis in metastatic prostate cancer. J Exp Clin Cancer Res. 2015;34(1):47.
108. Yim SY, Kang SH, Shin JH, Jeong YS, Oh SJ, Uhm SH, et al. Loss ARID1A expression is associated with poor prognosis in hepatocellular carcinoma. Cancer. 2020;120(9):2001–9.
109. He F, Li J, Xu J, Zhang S, Xu Y, Zhao W, et al. Decreased expression of ARID1A associates with poor prognosis and promotes metastases of hepatocellular carcinoma. J Exp Clin Cancer Res. 2015;34(1):47.
110. Cho HD, Lee JE, Jung HY, Oh MH, Lee JH, Jang SH, et al. Loss of ARID1A is a potential diagnostic marker in metastatic prostate cancer. J Exp Clin Cancer Res. 2015;34(1):47.
111. Xu N, Wang L, Sun P, Yu S, Sun Z. Low Arid1a expression correlates with poor prognosis and promotes cell proliferation and metastasis in osteosarcoma. Pathol Oncol Res. 2019;25(3):875–81.
112. Park JH, Lee C, Suh JH, Chae JY, Kim HW, Moon KC. Decreased ARID1A expression correlates with poor prognosis of clear cell renal cell carcinoma. Hum Pathol. 2015;46(3):454–60.
113. Lichner Z, Sconiat A, White NM, Voris AH, Rottstein L, Wiegand KC, et al. The chromatin remodeling gene ARID1A is a new prognostic marker in clear cell renal cell carcinoma. Am J Pathol. 2013;182(4):1163–70.
114. Kim MJ, Gu MJ, Chang HK, Yu E. Loss of ARID1A expression is associated with poor prognosis in small intestinal carcinoma. Histopathology. 2015;66(4):508–16.
115. Heine K, Nazeran TM, Lee S, Kramer P, Cairns ES, Chou DS, et al. Validated biomarker assays confirm that ARID1A loss is confounded with MMR deficiency, CD8(+) T-cell infiltration, and provides no independent prognostic value in endometriosis-associated ovarian cancers. J Pathol. 2022;256(4):388–401.
116. Itamochi H, Oumi N, Oishi T, Shoji T, Fujiwara H, Sugiyama T, et al. Loss of ARID1A expression is associated with poor prognosis in patients with stage IV clear cell carcinoma of the ovary. Int J Clin Oncol. 2015;20(5):967–73.
117. Ayhan A, Mao TL, Sekton T, Wu CH, Guan B, Ogawa H, et al. Loss of ARID1A expression is an early molecular event in tumor progression from ovarian endometriotic cyst to clear cell and endometrioid carcinoma. Int J Gynecol Cancer. 2012;22(8):1310–5.
118. Cho H, Kim JS, Chung H, Perry C, Lee H, Kim JH. Loss of ARID1A/BAF250a expression is linked to tumor progression and adverse prognosis in cervical cancer. Hum Pathol. 2013;44(7):1365–74.
119. Lowery WJ, Schildkraut JM, Akushevich L, Bentley R, Marks JR, Huntsman D, et al. Loss of ARID1A-associated protein expression is a frequent event in clear cell and endometrioid ovarian cancers. Int J Gynecol Cancer. 2012;22(1):9–14.
120. Maeda D, Mao TL, Fukayama M, Nakagawa S, Yano T, Takegai Y, et al. Clinicopathological significance of loss of ARID1A immunoreactivity in ovarian clear cell carcinoma. Int J Mol Sci. 2010;11(12):5120–8.
121. Yamamoto S, Tsuda H, Takano M, Tamai S, Matsubara O. PIK3CA mutations and loss of ARID1A protein expression are early events in the development of cystic ovarian clear cell adenocarcinoma. Virchows Arch. 2012;460(1):77–87.
122. Choi JY, Han HH, Kim YJ, Lee JH, Kim BG, Kang S, et al. Ovarian clear cell carcinoma sub‑typing by ARID1A expression. Yonsei Med J. 2017;58(1):59–66.
123. Katagiri A, Nakayama K, Rahman MT, Rahman M, Katagiri H, Ishikawa K, et al. Frequent loss of tumor suppressor ARID1A protein expression in adenocarcinomas/adenosquamous carcinomas of the uterine cervix. Int J Gynecol Cancer. 2012;22(2):208–12.
124. Heckl M, Schmoeckel E, Hertlein L, Rottmann M, Jeschke U, Mayr D. The deubiquitinase USP9X maintains DNA replication fork stability and DNA damage checkpoint responses by regulating CLASPIN during S-Phase. Cancer Res. 2016;76(8):2384–93.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.